In March 2025, the company declared new designs to get a direct-to-buyer offering of its Wegovy weight loss drug. The company established a different pharmacy, named NovoCare, which would demand shoppers $499 monthly for access to the drug, lower than half the price of the drug as a result of other pharmaceutical distribution networks.[fifty three]